BRAF identified as novel target for neuropathic pain treatment
Researchers at MD Anderson Cancer Center have discovered that the protein BRAF plays a critical role in chronic neuropathic pain. The study suggests that existing cancer drugs targeting BRAF could be repurposed to treat nerve pain by inhibiting pain signal amplification.
Why it matters
This discovery offers a potential pathway for rapid drug repurposing, which could provide relief for patients suffering from severe, treatment-resistant chronic pain.
Researchers at The University of Texas MD Anderson Cancer Center have identified a potential new target for treating chronic pain caused by nerve damage.
The article reports on scientific findings using objective, technical language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in